The acute effect of beta-guanidinopropionic acid versus creatine or placebo in healthy men (ABC-Trial): A randomized controlled first-in-human trial
Autor: | Lisa van der Woude, Deborah L. Horjus, Joseph F. Clark, Yentl C. Haan, Gajja S. Salomons, Lizzy M. Brewster, Rienk Nieuwland, Gert A. van Montfrans, Fares A. Karamat, Inge Oudman, Marianne C. L. Schaap |
---|---|
Přispěvatelé: | AGEM - Inborn errors of metabolism, AGEM - Endocrinology, metabolism and nutrition, Amsterdam Neuroscience - Cellular & Molecular Mechanisms, Clinical chemistry, Amsterdam Reproduction & Development (AR&D), ACS - Amsterdam Cardiovascular Sciences, Vascular Medicine, Graduate School, CCA -Cancer Center Amsterdam, Laboratory for Experimental Clinical Chemistry, ARD - Amsterdam Reproduction and Development, ACS - Pulmonary hypertension & thrombosis, ACS - Microcirculation, ACS - Atherosclerosis & ischemic syndromes |
Jazyk: | angličtina |
Rok vydání: | 2017 |
Předmět: |
Adult
Male medicine.medical_specialty Adolescent Guanidinopropionic acid Administration Oral macromolecular substances 030204 cardiovascular system & hematology Creatine Placebo Guanidines Drug Administration Schedule Young Adult 03 medical and health sciences chemistry.chemical_compound beta‐guanidinopropionic acid 0302 clinical medicine stomatognathic system Internal medicine Humans Medicine Clinical Trials Pharmacology (medical) tolerability Adverse effect Antihypertensive Agents Netherlands Pharmacology biology creatine kinase business.industry blood pressure Middle Aged Healthy Volunteers Intention to Treat Analysis Treatment Outcome Blood pressure Tolerability chemistry Pharmacodynamics Anesthesia biology.protein Creatine kinase Propionates business 030217 neurology & neurosurgery |
Zdroj: | British Journal of Clinical Pharmacology, 83(12), 2626-2635. Wiley-Blackwell Karamat, F A, Horjus, D L, Haan, Y C, van der Woude, L, Schaap, M C, Oudman, I, van Montfrans, G A, Nieuwland, R, Salomons, G S, Clark, J F & Brewster, L M 2017, ' The acute effect of beta-guanidinopropionic acid versus creatine or placebo in healthy men (ABC-Trial) : A randomized controlled first-in-human trial ', British Journal of Clinical Pharmacology, vol. 83, no. 12, pp. 2626-2635 . https://doi.org/10.1111/bcp.13390 British Journal of Clinical Pharmacology British journal of clinical pharmacology, 83(12), 2626-2635. Wiley-Blackwell |
ISSN: | 0306-5251 |
Popis: | Aims: Increasing evidence indicates that the ATP-generating enzyme creatine kinase (CK) is involved in hypertension. CK rapidly regenerates ATP from creatine phosphate and ADP. Recently, it has been shown that beta-guanidinopropionic acid (GPA), a kidney-synthesized creatine analogue and competitive CK inhibitor, reduced blood pressure in spontaneously hypertensive rats. To further develop the substance as a potential blood pressure-lowering agent, we assessed the tolerability of a sub-therapeutic GPA dose in healthy men. Methods: In this active and placebo-controlled, triple-blind, single-centre trial, we recruited 24 healthy men (18–50 years old, BMI 18.5–29.9 kg m−2) in the Netherlands. Participants were randomized (1:1:1) to one week daily oral administration of GPA 100 mg, creatine 5 g, or matching placebo. The primary outcome was the tolerability of GPA, in an intent-to-treat analysis. Results: Twenty-four randomized participants received the allocated intervention and 23 completed the study. One participant in the placebo arm dropped out for personal reasons. GPA was well tolerated, without serious or severe adverse events. No abnormalities were reported with GPA use in clinical safety parameters, including physical examination, laboratory studies, or 12-Lead ECG. At day 8, mean plasma GPA was 213.88 (SE 0.07) in the GPA arm vs. 32.75 (0.00) nmol l−1 in the placebo arm, a mean difference of 181.13 (95% CI 26.53–335.72). Conclusion: In this first-in-human trial, low-dose GPA was safe and well-tolerated when used during 1 week in healthy men. Subsequent studies should focus on human pharmacokinetic and pharmacodynamic assessments with different doses. |
Databáze: | OpenAIRE |
Externí odkaz: |